SERM (Selective Estrogen Receptor Modulator)

## Mechanism of Action

Selective estrogen receptor modulators (SERMs) work by binding to estrogen receptors (ERα and ERβ) located in various tissues throughout the body. Unlike estrogen, which uniformly activates these receptors, SERMs exhibit tissue-selective activity: they may activate estrogen receptors in bone (promoting bone density) while blocking them in breast tissue (reducing proliferation signals). This selectivity arises from differences in receptor conformation, coactivator and corepressor protein availability, and the specific SERM molecule's chemical structure.

In males, clomiphene and enclomiphene block estrogen receptors in the hypothalamus and pituitary gland. This blockade prevents negative feedback from endogenous estradiol, leading to increased secretion of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The rise in LH stimulates testicular Leydig cells to produce more testosterone, which is why these agents are sometimes used off-label for male hypogonadism.

## Clinical Use in Telehealth and Compounding

Clomiphene citrate (a racemic mixture of enclomiphene and zuclomiphene) has been used off-label in men to stimulate endogenous testosterone production. A 2013 study in the *Journal of Sexual Medicine* (PMID: 23635309) evaluated clomiphene citrate 25mg daily in 125 hypogonadal men and reported mean total testosterone increases from 230 ng/dL at baseline to 612 ng/dL after 3 months, with improvements in libido and energy.

Enclomiphene, the active isomer of clomiphene, has been studied specifically in male hypogonadism. A 2015 phase 3 trial (PMID: 26229740) randomized 306 hypogonadal men to enclomiphene 12.5mg or 25mg daily and observed dose-dependent increases in testosterone and LH, with a favorable safety profile over 24 weeks. While the FDA reviewed this data, enclomiphene is not currently an approved drug product for this indication. Compounded enclomiphene is available through licensed pharmacies pursuant to a valid prescription, but compounded enclomiphene is not an FDA-approved drug product.

In women, tamoxifen (approved by the FDA in 1977 for breast cancer) and raloxifene (approved by the FDA in 1997 for osteoporosis and breast cancer risk reduction) are established therapies. These molecules are not typically compounded, as branded and generic versions are widely available.

## Regulatory Status

Branded clomiphene citrate (Clomid, Serophene) received FDA approval for ovulation induction in women. Its use in male hypogonadism is off-label. Enclomiphene, as a single-isomer product, has not received FDA approval for any indication as of April 2025. Compounded enclomiphene preparations are prescribed by licensed providers under the discretion permitted by state and federal compounding laws, but these compounded preparations are not FDA-approved drug products.

Tamoxifen and raloxifene are FDA-approved for specific oncology and osteoporosis indications. Their mechanisms and safety profiles are well-characterized in the medical literature.

## Who Should Consider a SERM

Men who present with low testosterone and wish to preserve fertility or avoid exogenous testosterone therapy may discuss SERMs (clomiphene, enclomiphene) with a licensed provider. Women with estrogen-receptor-positive breast cancer or elevated fracture risk may be candidates for tamoxifen or raloxifene, respectively. These decisions are highly individual and require lab work, medical history review, and ongoing monitoring.

SERMs are contraindicated in individuals with a history of venous thromboembolism, active liver disease, or pregnancy. Side effects in men can include mood changes, visual disturbances (rare with clomiphene, requiring discontinuation), and variable libido changes. In women, hot flashes and thrombotic risk are known concerns with tamoxifen and raloxifene.

## When to Talk to a Provider

If you are experiencing symptoms of low testosterone (low libido, fatigue, reduced muscle mass, erectile dysfunction) or have been diagnosed with hypogonadism, ask your provider whether a SERM is appropriate for your case. If you have a history of blood clots, liver disease, or visual problems, disclose this information. SERMs require baseline labs (total testosterone, LH, FSH, estradiol, liver enzymes, lipid panel) and follow-up monitoring at 4-6 weeks and periodically thereafter.

Telehealth platforms like ZYNDIO connect you with licensed providers who can evaluate your history, order labs, and prescribe SERMs when clinically appropriate. ZYNDIO does not make treatment decisions; the provider does.

## FAQ

**What is the difference between clomiphene and enclomiphene?** Clomiphene citrate is a racemic mixture of two isomers: enclomiphene (the active enantiomer that blocks estrogen receptors and raises testosterone) and zuclomiphene (a weaker, longer-lasting isomer that may cause estrogenic side effects). Enclomiphene is the isolated active isomer and is thought to have a cleaner pharmacologic profile, though it is not currently an approved drug product.

**Can I take a SERM instead of testosterone replacement therapy?** SERMs stimulate your body's own testosterone production, whereas testosterone replacement shuts down endogenous production. Some men prefer SERMs to preserve fertility or avoid testicular atrophy. A licensed provider will evaluate your baseline testosterone, LH, FSH, and goals to determine which approach is appropriate.

**Are SERMs safe long-term?** Clomiphene has been used off-label in men for over a decade in clinical practice, with generally favorable short- to medium-term safety data. Long-term (>2 years) data in men are limited. Tamoxifen and raloxifene have decades of safety data in women, with well-characterized risks (venous thromboembolism, endometrial changes with tamoxifen). Any SERM requires periodic monitoring.

**Will my insurance cover a compounded SERM?** Most insurance plans do not cover compounded medications. ZYNDIO partners with state-licensed compounding pharmacies that offer transparent cash pricing. Check with your provider and the pharmacy for current costs.

**Can women use SERMs for hormone therapy?** Tamoxifen and raloxifene are used in specific oncology and osteoporosis indications in women. They are not used for general menopausal hormone replacement, as they can worsen hot flashes. Clomiphene and enclomiphene are used for ovulation induction and are not part of standard hormone therapy protocols.

**Medical Disclaimer**

The information in this article is for general education only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before starting, stopping, or changing any medication. ZYNDIO connects adults with licensed providers via telehealth; the providers—not ZYNDIO—make all clinical decisions. Compounded medications dispensed through ZYNDIO partners are not FDA-approved drug products. They are prepared by state-licensed compounding pharmacies pursuant to a valid prescription. Individual results vary. Side effects, drug interactions, and contraindications exist for every therapy discussed here.

Last reviewed: 2026-04-25 by ZYNDIO Clinical Editorial Team (PharmD-led)